3SBio Inc. (1530.HK)
Develops and sells biopharmaceutical drugs for cancer, blood disorders, and autoimmune diseases in China and internationally
17.38+0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-42.5%
The outlook
3SBio trades near its 52-week lows with a strong analyst consensus backing it and an average price target about 84% above current levels. The stock sits well below both its 50- and 200-day moving averages, indicating a weak recent trend. The low valuation multiple and bullish analyst lean contrast with the downward price momentum.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 10 analysts
Price trendBelow its 50- & 200-day averages
52-week range12% of the way from its 52-week low to high
Price targetAvg target +84% vs current price
Analyst price target
~12-month · 10 analysts32.01average target+84.2% vs now
Now 17.38
Low 23.01High 43.44
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$43.31B
52-wk high
36.80
52-wk low
14.81
50-day avg
17.39
200-day avg
23.46
Trailing P/E
4.4